|
|
| (95 intermediate revisions not shown) |
| Line 7: |
Line 7: |
| | </html> | | </html> |
| | | | |
| - | = Modelling = | + | = Modeling = |
| | | | |
| - | == ''in silico'' folding prediction ==
| + | Formation of modified Virus-Like Particles is key to the success of our project. Therefore we first [[Team:Wageningen_UR/InSilico|predict the structure of the subunits]] after which we use a [[Team:Wageningen_UR/FormationModel|model describing the formation of the whole VLPs]]. |
| | | | |
| - | === Introduction ===
| + | Finally, we wanted to know the applicability of our device. Therefore, we used a human body model which is based on the model made by the [[Team:Slovenia/ModelingPK|Slovenia 2012 iGEM team]]. We extensively modifyed this model to make it applicable for VLPs, their affinity with diseased tissue, the speed of excretion and degradation and finally, the drug delivery at the targeted tissue. |
| | | | |
| - | We designed the construction of the subunits based on tertiary structure models. These models are generated by the web-based tool [http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index Phyre2]. This server bases its prediction on both known structures and interactions between the amino acids. We used the tool to investigate whether the insertions and modifications cause any conformational changes to the subunits, which will most likely inhibit VLP formation.
| + | *[https://2012.igem.org/Team:Wageningen_UR/HumanBody Human Body Model] |
| - | | + | *[https://2012.igem.org/Team:Wageningen_UR/InSilico Tertiary Structure Modeling] |
| - | == Mathemathic VLP assembly model ==
| + | *[https://2012.igem.org/Team:Wageningen_UR/FormationModel VLP Assembly Model] |
| - | | + | |
| - | === Introduction ===
| + | |
| - | <p align="justify">
| + | |
| - | In our [[Team:Wageningen_UR/Project|project]] there are multiple aspects that we can model. Starting at the modelling of the formation of VLPs under different conditions, continuing at a dispersion model for when VLPs are injected into a human body and ending at marcro-models for degredation of VLPs in the environment.
| + | |
| - | We chose to model VLP formation and aggregate formation.
| + | |
| - | </p>
| + | |
| - | === VLP Formation ===
| + | |
| - | <p align="justify">
| + | |
| - | A VLP be a virus capsid without any genetic materialconsistsof a certain number of subunits or monomers. These subunits are viral proteins, which for our project are made to be expressed by E.coli and then made to re-assemble in vitro.
| + | |
| - | <br><br>
| + | |
| - | For modelling our VLPs we needed to find a model which could fit the assembly of our entire virus like particles, namely, CCMV, HBV and PLRV.In the case of CCMV, there are 180 subunits which go on to form capsomeres in the form of pentamers or hexamers and self-assemble according to the triangulation number, T=7 to form a capsid approximately 28nm in diameter. The CCMV capsid consists of 12 pentameric capsomeres and 20 hexagonal ones. But for the sake of modelling, we take an average of it forming 36 pentameric capsomeres.
| + | |
| - | <br><br>
| + | |
| - | Presently, assembly of virus particles is not fully understood and different idealized models and theories are present which try to explain the assembly process. One such theory is the classical nucleation theory. In this the first step is the self-association reaction which begins with a nucleation event (the formation of a dimer). This dimer then serves as the basis for elongation through sequential addition of free subunits, one at a time, to nuclei to form partially assembled intermediates which results in a closed icosahedral VLP. Nucleus formation is regarded as the rate-limiting step.
| + | |
| - | <br><br>
| + | |
| - | We chose this model because it competitively accounts for the partitioning of the protein subunits between correct and the aggregation pathways. This can lead to estimating the yield of the VLPs once the parameters have been estimated.
| + | |
| - | <br><br>
| + | |
| - | The critical concentration of capsomeres is the concentration below which no VLP formation will take place. Therefore, to be able to form VLP's, the total concentration of capsomeres should be higher than the critical concentration. To establish this, we assume the concentration of capsomeres available for VLP formation (C) to be equal to the total concentration (C<sub>total</sub>) minus the critical concentration (C<sub>critical</sub>):
| + | |
| - | <br><br>
| + | |
| - | (1) C = C<sub>total</sub> – C<sub>critical</sub>
| + | |
| - | <br><br>
| + | |
| - | It is considered that a dimer is the first species (nucleus) formed in the reaction, and is subsequently consumed to form higher-order intermediates by the addition of free subunits (capsomeres). Two capsomeres will go on to form a dimer (rate limiting step), whose concentration is defined by C<sub>2</sub>. The rate of change of concentration of dimers with time, depends on k<sub>v,critical</sub> (M<sup>-1</sup> s<sup>-1</sup>) which is the nucleation rate constant and k<sub>v</sub> (M<sup>-1</sup> s<sup>-1</sup>) the elongation rate constant, given by the equation:
| + | |
| - | <br><br>
| + | |
| - | (2) dC<sub>2</sub>/d<sub>t</sub> = (1/2) * k<sub>v,critical</sub> * C^2 – k<sub>v</sub> * C * C<sub>2</sub>
| + | |
| - | <br><br>
| + | |
| - | The aggregation of the viral protein is modelled by a second-order reaction describing the agglomeration of two capsomeres, where A is the aggregate concentration and k<sub>A</sub> (M-1 s-1) the aggregation rate constant.
| + | |
| - | <br><br>
| + | |
| - | (3) dA/dt = (1/2) * k<sub>A</sub> * C<sub>2</sub>
| + | |
| - | <br><br>
| + | |
| - | The capsomere concentration will continuously drop, depending on the rate of dimer formation, elongation and aggregate formation. This equation is given by:
| + | |
| - | <br><br>
| + | |
| - | (4) dC/dt = k<sub>V,critical</sub> * C^2 - k<sub>V</sub> * C * ∑_(i=2)^(s-1) C<sub>i</sub> - k<sub>A</sub> * C^2
| + | |
| - | <br><br>
| + | |
| - | On the path to the formation of the VLP, due to elongation intermediates are formed, with the first one (3 capsomeres long) forming after the elongation of a dimer. The equation for the formation of intermediates, with i being the number of subunits in a given intermediate, is given by:
| + | |
| - | <br><br>
| + | |
| - | (5) dC<sub>i</sub>/dt = k<sub>V</sub> *C * (C<sub>i-1</sub> - C<sub>i</sub>); i= 3; 4; . . . ; s-1
| + | |
| - | <br><br>
| + | |
| - | The last step of the process is the formation of the VLP. The VLP concentration is the end result of the elongation to the biggest possible intermediate (s-1), s being the number of subunits in a correctly formed VLP:
| + | |
| - | <br><br>
| + | |
| - | (6) dV/dt = k<sub>V</sub> * C * C<sub>s-1</sub>
| + | |
| - | <br><br>
| + | |
| - | where V is the VLP concentration, s is the number of subunits in a correctly formed VLP (36 in the case of CCMV), and i is the number of subunits in a given intermediate. The initial conditions at t=0 were set as C=C<sub>0</sub> and C<sub>2</sub> = C<sub>3</sub> =...... = C<sub>35</sub>= V=A=0.
| + | |
| - | <br><br>
| + | |
| - | The initial conditions at t=0 are C=C0 and C2 = C3 =...... = C35= V=A=0.
| + | |
| - | <br><br>
| + | |
| - | For our model, we ran simulations using MATLAB 2012. Values for the parameters, Ccritical ,Kv,critical,Kv and KA were assumed. It should be noted that, since the rate constants would be in M<sup>-1</sup> s<sup>-1</sup> and the concentration in mg/ml, an intermediate C<sub>i</sub> would weigh i times the weight of a capsomere. So, in the end, the VLP would weigh s times the weight of a capsomere. This was introduced into our model script and the resulting simulation was obtained.
| + | |
| - | <br><br>
| + | |
| - | [[File:Graph.jpg|500px|center|thumb|Figure 1: ...</p>]]
| + | |
| - | <br><br>
| + | |
| - | The parameters can then be determined by carrying out experiments to measure the concentration of the protein by curve fitting with the simulations. This can also be achieved in MATLAB. Thus, one would be able to minimize losses through aggregation.
| + | |
Finally, we wanted to know the applicability of our device. Therefore, we used a human body model which is based on the model made by the Slovenia 2012 iGEM team. We extensively modifyed this model to make it applicable for VLPs, their affinity with diseased tissue, the speed of excretion and degradation and finally, the drug delivery at the targeted tissue.
"
